Business
Result of General Meeting
Result of General Meeting.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\", the \"Company\" or the \"Group\")\n \nResult of General Meeting\n \n31 July 2023: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that at the General Meeting today, held for the purposes of approving the Company's annual report and accounts for the year ended 30 June 2022 (the \"2022 Accounts\"), all resolutions were duly passed.\n \nAll resolutions were voted on by way of a poll. The results of the poll were as follows:\n \n\n\n\nResolution\n\n\nVotes For\n\n\n% of votes for \n\n\nVotes Against\n\n\n% of votes against\n\n\nVotes Withheld\n\n\nTotal votes cast\n\n\n\n\n1. To receive the Directors' report, the consolidated financial\nstatements and the auditors' report of the Company for the year\nended 30 June 2022 (the \"2022 Accounts\")\n\n\n332,831,805\n\n\n99.75%\n\n\n822,693\n\n\n0.25%\n\n\n97,047\n\n\n333,751,545\n\n\n\n\n2. To approve the Directors' remuneration report, as set out on\npages 64 to 72 of the 2022 Accounts\n\n\n330,801,478\n\n\n99.27%\n\n\n2,443,679\n\n\n0.73%\n\n\n506,388\n\n\n333,751,545\n \n\n\n\n \n \n- ENDS -\n \nFor further information, please contact:\n \nAllergy Therapeutics\nManuel Llobet, Chief Executive Officer\nMartin Hopcroft, Interim Chief Financial Officer\n+44 (0)1903 845 820\n \nPanmure Gordon (Nominated Adviser and Broker)\nFreddy Crossley, Emma Earl, Corporate Finance\nRupert Dearden, Corporate Broking\n+44 (0)20 7886 2500\n \nConsilium Strategic Communications\nMary-Jane Elliott / David Daley / Davide Salvi\n+44 (0)20 3709 5700\[email protected]\n \n \nNotes for editors:\n \nAbout Allergy Therapeutics\n \nAllergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Fo...